在COVID-19急性呼吸窘迫综合征的体外膜氧化后发生的Enterococcus faecium EMPYEMA
Mark R Brown1, Joshua M Boster2, Stephen M Goertzen3
1Internal Medicine, San Antonio Military Medical Center, San Antonio, USA.
Cureus
|September 4, 2023
概括
一名患有严重COVID-19的患者在体外膜氧化 (ECMO) 支持后发生了由Enterococcus faecium引起的罕见肺. 内组织等离子体激活剂 (tPA) 和多纳酶α (DNase) 成功地解决了感染.
科学领域:
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
- 肺部病理学 肺部病理学
背景情况:
- 严重的COVID-19通常需要体外膜氧化 (ECMO).
- 经ECMO后的并发症可能包括严重的感染,比如膜静脉瘤.
- 肠球菌 (Enterococcus faecium) 是一种不寻常的病原体,尤其是在这种情况下.
研究的目的:
- 报告一种罕见的Enterococcus faecium empyema病例,患者从严重的COVID-19和ECMO支持中恢复过来.
- 描述使用内组织等离子体激活剂 (tPA) 和多纳酶α (DNase) 的成功治疗这种.
- 为了突出COVID-19,ECMO和Enterococcus faecium empyema之间的不同寻常的关联.
主要方法:
- 一名33岁的男性患者患有严重的COVID-19,在ECMO治疗中,在脱后出现了empyema.
- 最初的治疗包括管胸腔切除术和抗生素,由于抗凝剂而未能进行盐水洗.
- 进行了tPA和DNase的内注射.
主要成果:
- 内tPA和DNase治疗导致Enterococcus faecium empyema的成功解决.
- 尽管患者需要全身抗凝药,但治疗仍然安全地进行.
- 这种病例代表了Enterococcus faecium empyema与COVID-19和ECMO的新兴关联.
结论:
- 脑内tPA和DNase为危急病患者的复杂 empyema 提供了安全有效的治疗方法,即使是服用抗凝药的患者.
- 应考虑Enterococcus faecium在COVID-19后患者的肺的差异诊断中,特别是那些接受过ECMO的患者.
- 这一案例扩大了对与严重的COVID-19相关的传染性并发症及其管理的理解.
关键词:
这是一种抗凝血药物.在COVID-19中,有很多人.这就是ECMOECMO的意义.肠球菌 (enterococcus faecium) 是一个有毒的菌株.胸腔内膜炎是什么意思 胸腔内膜炎是什么意思静脉 - 静脉的生态环境在vv ecmo ecmo更多相关视频
相关概念视频
01:29Acute Respiratory Failure-V
161
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
161
01:21Acute Respiratory Failure-II
270
Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
270
01:30Acute Respiratory Failure-III
219
Hypercapnic respiratory failure, also known as Type 2 or ventilatory respiratory failure, is a severe condition characterized by the body's inability to effectively remove carbon dioxide (CO2) from the bloodstream. It leads to an arterial CO2 pressure (PaCO2) exceeding 45 mmHg and a blood pH above 7.35. This situation indicates that the body's ventilatory demand, or the ventilation needed to maintain normal PaCO2 levels, surpasses its supply or the maximum gas flow achievable without...
219
01:21Acute Respiratory Failure-I
244
Acute respiratory failure is a condition characterized by the inability of the lungs to perform their primary function: gas exchange. This failure leads to insufficient oxygen levels (hypoxemia) in the blood, elevated carbon dioxide levels (hypercapnia), or both, causing critical impairment in organ function.
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
Definition: It is defined by specific criteria based on blood gas measurements. Hypoxemia happens when the partial pressure of oxygen (PaO2) falls below 60 mmHg. At the same time,...
244
01:30Pneumonia III: Complications and Assessment
261
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
261
01:28Pneumonia IV: Management
359
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
359